Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2002

View Archived Issues

Avant's cholera vaccine enters phase II study

Targeted Genetics completes enrollment in phase II study of tgAAVCF in cystic fibrosis

SC-51 inhibits exhaled breath NO in normal and asthmatic subjects

Andolast pretreatment reduces AMP-induced airways hyperresponsiveness

Novel antiobesity agents presented by Sanofi-Synthelabo

Trypsin-like serine protease inhibitors patented by BioCryst

New cholesterol-lowering agents in development at Ilex Oncology

VEGF antagonists identified at Ark Therapeutics

Pfizer claims endothelin ETA antagonists for cardiovascular disorders

Merck discovers new antidiabetic PPAR agonists

Indoles as tissue-selective estrogen receptor modulators and their use

New LTB4 antagonists patented by Boehringer Ingelheim

Fidarestat reverses cellular responses to high glucose concentrations

Statins may be effective for the treatment of certain diabetic complications

Morphological and functional improvement seen in Ro-444753-treated rats with emphysema

Novel PDE4 inhibitor Ono-6126 with potential in asthma, low emetogenic liability

Selective inhibition of eosinophil adhesion to VCAM-1 demonstrated for new VLA-4 inhibitor

Neutrophil infiltration directly involved in the development of airways hyperresponsiveness

Caspase inhibitor improves liver function tests with good safety in first clinical trial

Studies using SB-203580 demonstrate involvement of p38 kinase in colon cancer

GLP-2 analogue provides clinical, functional and structural improvement in SBS patients

Cell Pathways to initiate early experience program for Gelclair

Neutrophil elastase inhibitor reported to have beneficial effects in guinea pig model of emphysema

Novartis launches TARGET trial of Prexige in arthritis

FDA approves Zoloft for premenstrual dysphoric disorder

Phase II enrollment completed for dalbavancin in complicated skin and soft tissue infections

Celltech and Amgen to research and develop novel osteoporosis treatments

Orphan Medical submits complete response to Xyrem approvable letter

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...